Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: John Romeo who wrote (10828)	7/17/1999 8:30:00 AM
From: Robert K.	Read Replies (2) \| Respond to of 17367

John, I believe that bpi will only limit complement when the stimulus is lps. If the stimulus is lps then I believe you have potential for a bpi or lbp type product. Cacaito its the expert on this stuff. I defer to him. I hope he jumps into the discussion and corrects and adds to my thoughts. However, I continue to think about the likenesses of hu1124 and bpi regarding inhibition. Perhaps Cacaito could clarify this also and add his usual insight. Some of the things bpi is known(thought to) to inhibit are, 1. bacteria 2. fungi and other pathogens(thru platform) 3. heparin 4. heparan 5 e-selection 6. complement at c3 something 7. tnf 8. IL-1 9. IL-6 10. IL-8 11. lps (block) 12. phagocytosis (bpi21) Thats all I can think of right now, therein lies many of the potentials. >>>>>>>>>>>>>>>>>>>>>standard K.